Source-grounded facts extracted from Celldex Therapeutics, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sam Martin departed as Senior Vice President and Chief Financial Officer at Celldex Therapeutics, Inc..
“On July 10, 2026, Sam Martin, Senior Vice President and Chief Financial Officer of Celldex Therapeutics, Inc. (the “Company”), notified the Company of his plans to retire effective on or about March 31, 2027.”
Celldex Therapeutics, Inc. reported financial results for first quarter ended March 31, 2026.
“On May 7, 2026, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter of 2026.”
Celldex Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters valued at approximately $282 million (effective 2026-04-01).
“On April 1, 2026, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and TD Securities (USA) LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 10,345,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $29.00 per share (the “Offering”).”
Celldex Therapeutics, Inc. reported financial results for first quarter ended March 31, 2024.
“On May 6, 2024, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the first quarter of 2024.”
Celldex Therapeutics, Inc. entered into Underwriting Agreement with Leerink Partners LLC and Cowen and Company, LLC valued at approximately $376.2 million (effective 2024-02-29).
“On February 29, 2024, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC and Cowen and Company, LLC (the “Representatives”), as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 8,520,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $47.00 per share (the “Offering”). The net proceeds to the Company from the Offering are expected to be approximately $376.2 million, after deducting underwriting discounts and commissions and other estimated offering expenses payable by the Company.”
Celldex Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.
“On February 26, 2024, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the fourth quarter and year ended 2023.”
Celldex Therapeutics, Inc. entered into Underwriting Agreement with Jefferies LLC and Leerink Partners LLC, as representatives of the several underwriters (effective 2023-11-07).
“On November 7, 2023, Celldex Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Jefferies LLC and Leerink Partners LLC (the “Representatives”), as representatives of the several underwriters named therein (the “Underwriters”), relating to the offering, issuance and sale of 7,425,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 (the “Common Stock”), at a price to the public of $27.00 per share (the “Offering”).”
Celldex Therapeutics, Inc. reported third quarter ended September 30, 2023 results: revenue $1.5 million.
“activities of $19.0 million for the three months ended September 30, 2023. At September 30, 2023, Celldex had 47.3 million shares outstanding. Revenues: Total revenue was $1.5 million in the third quarter of 2023 and $2.8 million for the nine months ended September 30, 2023, compared to $0.4 million and $0.7 million for the comparable periods in 2022. The”
Celldex Therapeutics, Inc. reported financial results for the second quarter ended June 30, 2023.
“On August 8, 2023, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the second quarter of 2023.”
Celldex Therapeutics, Inc. shareholders approved Advisory, non-binding recommendation on the preferred frequency of advisory stockholder votes on the compensation of our named executive officers at the 2023-06-15 meeting.
“5. The stockholders voted to recommend, on an advisory, non-binding basis, the preferred frequency of advisory stockholder votes on the compensation of our named executive officers. The tabulation of votes with respect to this proposal was as follows: 1 Year 2 Year 3 Year Abstain Broker Non-Votes 39,023,941 28,372 596,115 115,683 3,865,440”
Celldex Therapeutics, Inc. shareholders approved Advisory, non-binding approval of the compensation for the Company’s named executive officers as disclosed in the Proxy Statement at the 2023-06-15 meeting.
“4. The stockholders voted to approve, on an advisory, non-binding basis, the compensation for the Company’s named executive officers as disclosed in the Proxy Statement. The tabulation of votes with respect to this proposal was as follows: For Against Abstain Broker Non-Votes 38,667,727 981,947 114,437 3,865,440”
Celldex Therapeutics, Inc. shareholders approved Amendment to 2021 Omnibus Equity Incentive Plan, including an increase in shares reserved for issuance by 600,000 shares to 4,300,000 shares at the 2023-06-15 meeting.
“3. The stockholders approved an amendment to our 2021 Omnibus Equity Incentive Plan, including an increase in the number of the shares reserved for issuance thereunder by 600,000 shares to 4,300,000 shares. The tabulation of votes with respect to this proposal was as follows: For Against Abstain Broker Non-Votes 30,227,954 9,422,093 114,064 3,865,440”
Celldex Therapeutics, Inc. shareholders approved Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023 at the 2023-06-15 meeting.
“2. The stockholders approved the ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2023. The tabulation of votes with respect to this proposal was as follows: For Against Abstain 43,417,304 98,580 113,667”
Celldex Therapeutics, Inc. shareholders approved Election of directors to serve until the 2024 annual meeting at the 2023-06-15 meeting.
“1. The stockholders elected the following individuals to serve on the Company’s board of directors until the annual meeting of stockholders to be held in 2024. The tabulation of votes with respect to the election of such directors was as follows: Nominees For Against Abstain Broker Non-Votes Karen L. Shoos (Chair of the Board) 39,439,326 216,612 108,173 3,865,440 Anthony S. Marucci (Chief Executive Officer) 39,483,824 173,987 106,300 3,865,440 Keith L. Brownlie 39,345,213 309,126 109,772 3,865,440 Cheryl L. Cohen 39,228,229 426,357 109,525 3,865,440 Herbert J. Conrad 35,753,401 3,901,608 109,102 3,865,440 Rita I. Jain, M.D. 39,608,126 47,159 108,826 3,865,440 James J. Marino 39,484,114 170,691 109,306 3,865,440 Garry A. Neil, M.D. 33,452,228 6,202,305 109,578 3,865,440 Harry H. Penner, Jr. 39,462,062 192,380 109,669 3,865,440”
Celldex Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2023.
“Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the first quarter ended March 31, 2023”
Celldex Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2022.
“Celldex Therapeutics, Inc. (NASDAQ:CLDX) today reported financial results for the fourth quarter and year ended December 31, 2022”
Rita Jain, M.D. was appointed as member of the Board of Directors at Celldex Therapeutics, Inc..
“Rita Jain, M.D. was appointed as a member of our Board of Directors (the “ Board ”) on February 16, 2023.”
Celldex Therapeutics, Inc. reported financial results for third quarter of 2022.
“On November 9, 2022, Celldex Therapeutics, Inc. (the "Company") issued a press release announcing its financial results for the third quarter of 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.